CD274 and small cell lung carcinoma: We also previously reported that SP142 was the only one of three validated PD-L1 assays with a significant difference in survival among patients with SCLC; patients with SP142 expression had a longer OS with more distinct differences in ES, relative to limited-stage patients [22].